<DOC>
	<DOCNO>NCT01729663</DOCNO>
	<brief_summary>Randomized , open , Phase II-III study , comparative treatment CSF-470 vaccine , allogeneic , irradiate BCG molgramostin ( rHuGM-CSF ) adjuvant interferon alfa 2b ( IFN-alpha2b ) treatment , stage IIB , IIC III ( AJCC ) post-surgery cutaneous melanoma patient . This study approve ANMAT ( Administración Nacional de Medicamentos , Alimentos Tecnología Médica ( ANMAT ) ) , number 1556/2011 ( www.anmat.gov.ar ) . The study Institution Instituto Médico Especializado Alexander Fleming , Ciudad Autónoma de Buenos Aires , Argentina . The Sponsor Laboratory Pablo Cassará ( LPC , S.R.L. ) . Study population include total 108 patient ( 72 patient receive CSF470 vaccine 36 patient receive alpha IFN-alpha 2b ) total 24 month . CSF-470 treatment consist four vaccine dos id injection ( three week apart ) , one dose every two month first year every three month second year . Each vaccine consist mixture 17,6.106 melanoma cell , four melanoma cell line , genetically modify lethally irradiate . As adjuvant BCG ( 120 µg prot ) first day rHuGM-CSF ( Molgramostim , 400 µg , fractionate four day dos ) use . IFN-alpha 2b treatment consist s.c. injection 10 million unit ( MU ) ( 5 t/w ) four week 5 MU ( 3t/w ) 23 month . Both treatment also compare quality life ( QOL ) study possible correlation CSF470 vaccine arm induce immune response clinical outcome</brief_summary>
	<brief_title>Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF v IFN Alpha 2b Stage IIB , IIC III Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<mesh_term>Molgramostim</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>histologically confirm cutaneous melanoma stage IIB , IIC III ( AJCC ) patient nondetectable disease ( NED ) surgery assert CAT scan . Melanoma pts unknown primary tumor site could include study life expectancy &gt; 6 month performance status ( ECOG ) 0 1 Time post surgery 4 month chemotherapy , radiotherapy biological treatment prior study . patient must CATscans brain , thorax , abdomen pelvis 60 previous day trial enrol To laboratory study ( 15 day enter study ) laboratory eligibility criterion include : hematocrit : ≥35 ( hemoglobin &gt; 10,5 gr % ) ; WBC count &gt; 3500/mm3 , platelet &gt; 100.000/mm3 , total direct bilirubin , serum oxalacetic transaminase glutamic pyruvic transaminase &lt; 1.5 fold upper normal value ; LDH ≤ 450 mU/ml negative serology HIV , antiHCV HBsAg serum creatinine &lt; 2.0 mg % patient must give write informed consent inclusion Study . Pregnant breastfeed woman Diabetes ( Type I II ) Antecedents psychiatric disease Evidence active infection Antecedents viral autoimmune hepatitis Previous autoimmune disease Morbid Obesity , define CMI ( Corporal mass index ) &gt; 37 kg/m2 woman &gt; 40 kg/m2 men . Other disease require treatment regular corticoid non steroid antiinflammatory drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>melanoma</keyword>
	<keyword>irradiated-allogeneic cell</keyword>
	<keyword>therapeutic vaccine</keyword>
	<keyword>Interferon alpha 2-b</keyword>
</DOC>